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Abstract
Background: Subarachnoid hemorrhage (SAH) is a devastating neurological injury with high morbidity and
mortality that is mainly caused by early brain injury (EBI). Progranulin (PGRN) is known to be involved in various
biological functions, such as anti-inflammation and tissue repair. This study aimed to investigate the change of
PGRN in the brain after SAH and its role on EBI.
Methods: The levels of PGRN, myeloperoxidase (MPO), interleukin1β (IL-1β), and tumor necrosis factor-α (TNF-α)
were detected in the cerebrospinal fluid (CSF) from SAH patients by enzyme-linked immunosorbent assay (ELISA). In
addition, PGRN levels were also detected in the cerebral cortex after experimental SAH in rats by western blotting
and immunohistochemistry (IHC). Recombinant human PGRN (r-PGRN) or an equal volume of phosphate-buffered
saline (PBS) was administrated at 30 min after SAH. All rats were subsequently sacrificed at 24 h after SAH.
Neurological score and brain water content were assessed. For mechanistic studies, the changes of MPO, matrix
metalloproteinase-9 (MMP-9), zonula occludens 1 (ZO-1), Bcl-2, and cleaved caspase-3 were examined by western
blotting and the levels of pro-inflammatory cytokines (IL-1β and TNF-α) were determined by ELISA. In addition,
neuronal apoptosis and blood brain barrier (BBB) permeability were examined.
Results: The levels of PGRN significantly decreased, and the levels of MPO, IL-1β, and TNF-α were markedly
elevated in the CSF from SAH patients. In rats, PGRN levels in the brain also decreased after SAH. Administration of
r-PGRN decreased brain water content and improved neurological scores at 24 h after SAH. These changes were
associated with marked reductions in MPO, MMP-9, and proinflammation cytokine levels, as well as increased levels
of Bcl-2 and ZO-1. In addition, neuronal apoptosis and BBB permeability were alleviated by r-PGRN.
Conclusions: These results indicate that the levels of PGRN decreased after SAH and that r-PGRN alleviates EBI after
SAH possibly via inhibition of neutrophil recruitment, providing a new target for the treatment of SAH.
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Background
Subarachnoid hemorrhage (SAH) is a life-threatening
cerebrovascular disease that is mainly caused by ruptured
aneurysms and has a morbidity and mortality rate higher
than 50 % [1]. Recent studies have demonstrated that early
brain injury (EBI), and not cerebral vasospasm (CVS), is
the most important cause of the high morbidity and mor-
tality. EBI is the immediate injury to the brain within 72 h
after SAH [2] and strongly determines the prognosis of
SAH patients [3]. Several physiological derangements
occur during EBI, including increasing intracranial pres-
sure, decreasing cerebral blood flow, and global cerebral
ischemia [4]. These immediate events initiate secondary
injuries, such as inflammation, blood brain barrier (BBB)
disruption, cell death, and oxidative cascades [5]. Numer-
ous findings have highlighted that inflammatory reactions
are the major contributor to EBI [6–8]. Neutrophils play
an important role in inflammatory reactions. Neutrophils,
which are induced by inflammation, migrate into brain
issue, exaggerate the inflammatory reaction, reduce cere-
bral blood flow, and aggravate brain injury [9]. In addition,
neutrophils contribute to BBB disruption, brain edema,
and neural cell injury by releasing proteases, cytokines,
and chemokines [10, 11].
Progranulin (PGRN) is a 593 amino acid, cysteine-rich
protein of 68.5 kDa that is typically secreted in a highly
glycosylated 88 kDa form [12] and expressed ubiqui-
tously throughout the body [13]. In the central nervous
system (CNS), it is detected in neurons and microglia,
but in astrocytes and ependymal cells, little or no PGRN
is detected [14–16]. It is reported that PGRN performs
various biological functions, such as the regulation of
cell growth, embryonic development, tissue repair, and
the modulation of inflammation [17, 18]. Recently, the
anti-inflammatory effects of PGRN in various states were
reported, including acute lung injury, neurodegenerative
diseases and ischemic stroke [19–21]. PGRN has been
reported to have anti-inflammatory properties that may
prevent brain injury by reducing the release of pro-
inflammatory cytokines or elevating the release of anti-
inflammatory factors [22]. In addition, PGRN-deficient
mice displayed exaggerated inflammation compared with
wild types [23].
However, until now, no study has focused on the anti-
inflammatory effects of PGRN in SAH. In the present
study, we investigated the time course of PGRN levels in
cerebrospinal fluid (CSF) of SAH patients. In addition, the
time course and anti-inflammatory effects of PGRN were
explored in the brains of rats after experimental SAH.
Methods
Ethics statement
All procedures in the human study were approved by
Jinling Hospital’s medical institutional review board and
were all performed in accordance with the Declaration
of Helsinki.
All experimental protocols including animal use and
surgical procedures were approved by the Animal Care
and Use Committee of Jinling Hospital and conformed
to the Guide for the Care and Use of Laboratory
Animals by the National Institutes of Health.
Human CSF preparation
CSF was obtained from 43 SAH patients and 4 joint re-
placement patients (control group). The patients were
divided into a control group (n = 4) and three SAH
groups based on the time after SAH: 1–3 days (n = 16),
4–7 days (n = 18), and ≥8 days (n = 9). The injury sever-
ity scores including Hunt&Hess grade, Modified Fisher
grades, World Federation of Neurological Surgeons
(WFNS) Grading System, and Glasgow Coma Scale
(GCS) were immediately recorded for SAH patients after
admission to the hospital. The CSF was obtained
through lumbar puncture and during surgery. After
centrifugation (3000 g, 5 min), the supernatant of
CSF was collected and stored at −80 °C. The clinical
outcomes of these patients were evaluated at discharge ac-
cording to Glasgow Outcome Scale (GOS) and Modified
Rankin Scale (MRS). Detailed information was presented
in Table 1.
Animal preparation and experiment design
Male Sprague–Dawley (SD) rats (280–320 g) were pur-
chased from the Animal Center of Jinling Hospital,
Jiangsu, China. The rats were raised under a 12-h light/
dark cycle (25 ± 1 °C) and had free access to food and
water at the Animal Center of Jinling Hospital.
Rats were randomly divided into six groups: sham,
12 h, and 1, 3, 5, and 7 days SAH groups, respectively.
Rats were sacrificed for sample collection at the corre-
sponding time points after SAH.
Based on PGRN results, we increased the levels of
PGRN and sacrificed all animals at 24 h after SAH. Re-
combinant human PGRN (r-PGRN) (R&D Systems, Inc.,
Minneapolis, MN, USA) (r-PGRN in 5 μL of phosphate-
buffered saline (PBS)) or an equal volume of PBS were
administrated at 30 min after SAH through a single in-
tracerebroventricular (i.c.v.) injection [24]. Animals were
randomly divided into seven groups: sham, SAH, SAH +
PBS, and SAH + PGRN (1, 3, 10, and 15 ng per rat). Ini-
tially, four concentrations were used to test the neuro-
protective effects of r-PGRN on EBI after SAH. We
chose these doses based on an ischemic stroke study
[19]. Neurologic scores and brain water content were
measured at 24 h after SAH. In the second set of experi-
ments, which were based on our initial study, rats were
treated with a dose of r-PGRN that gave the most
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Table 1 Clinical data from control and SAH cases
Case no Age (year)/sex Aneurysm location Time after SAH (day) Hunt&Hess grade Fisher grade WFNS GCS GOS MRS
1 57/F ACOA 1 3 4 2 13 3 3
2 57/F ACOA 5 3 4 2 13 3 3
3 69/M LACA 5 4 – 5 3 2 5
4 57/F ACOA 6 3 4 2 13 3 3
5 69/M LACA 6 4 – 5 3 2 5
6 57/F ACOA 7 3 4 2 13 3 3
7 69/M LACA 11 4 – 5 3 2 5
8 50/F LMCA 3 2 2 1 15 3 4
9 57/F ACOA 14 3 4 2 13 3 3
10 57/F ACOA 15 3 4 2 13 3 3
11 63/M ACOA 4 5 4 5 3 2 5
12 67/F LICA 5 4 4 5 4 5 1
13 68/F RPCOA 6 3 2 2 14 5 1
14 52/M LMCA 1 4 4 4 7 3 5
15 54/M LMCA 8 2 2 1 15 1 –
16 51/F ACOA 15 2 3 2 7 3 4
17 58/F ACOA 2 1 2 1 15 5 0
18 51/F LICA 3 3 3 4 10 5 1
19 67/F RPCOA 3 2 3 1 15 1 –
20 66/F ACOA 2 1 3 3 15 5 1
21 67/F RPCOA 6 2 3 1 15 1 –
22 62/F ACOA 5 2 3 1 15 3 4
23 65/F ACOA 5 2 2 1 15 5 0
24 58/M ACOA 3 4 4 4 7 3 4
25 59/M RMCA 4 2 2 1 15 5 1
26 59/M RICA 4 5 4 5 3 2 5
27 43/F LMCA 4 2 2 1 15 5 0
28 66/F LPCOA 2 2 2 1 15 5 0
29 67/F ACOA 1 2 2 2 14 4 2
30 59/M RICA 20 5 4 5 3 2 5
31 67/F ACOA 3 2 2 2 14 4 2
32 45/M ACOA 10 2 2 1 15 3 4
33 46/F ACOA 1 2 2 1 15 5 0
34 48/M ACOA 2 2 2 1 15 5 0
35 59/M ACOA 6 4 4 5 5 3 4
36 50/F RMCA 2 3 2 2 13 3 4
37 59/M ACOA 14 4 4 5 5 3 4
38 38/F BT 1 3 4 4 8 4 2
39 38/F BT 4 3 4 4 8 4 2
40 59/M ACOA 1 5 4 5 3 3 4
41 50/F RMCA 6 3 2 2 13 3 4
42 38/F BT 10 3 4 4 8 4 2
43 69/M LACA 4 4 – 5 3 2 5
44 58/M – – – – – – – –
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marked effect for further studies. Six rats were used in
each group.
Animal model of SAH
Experimental SAH models were produced as reported
previously [25]. In brief, the rats were anesthetized with
chloral hydrate (0.4 mg/kg, IP, Jinling Hospital). The
head and inguinal region was carefully shaved and disin-
fected. Rats were then fixed in a stereotaxic apparatus. A
midline scalp incision was made and a 1-mm hole was
drilled 8.0 mm anterior to Bregma in the midline. To
prevent loss of CSF and bleeding from the midline ves-
sels, we used bone wax to plug the burr hole. Rats were
placed in the supine position and an insulin syringe (BD
Science) was used to draw 300 μL of nonheparinized
blood from the femoral artery. The needle was advanced
11 mm into the prechiasmatic cistern through the burr
hole, at a 45° angle to the vertical plane, and then
300 μL of blood was injected into the prechiasmatic cis-
tern over 20 s. An equal volume of normal saline was
injected into the prechiasmatic cistern of rats in the
sham group (Fig. 1). The burr hole was sealed with bone
wax, and the incision was surgically sutured. Rats were
kept at 30 °C, with their head placed in a downward pos-
ition for 20 min. After recovery from anesthesia, the rats
were returned to their cages and housed at 25 ± 1 °C.
Rats that died during surgery or surgical recovery
were excluded from the study, and the procedure was
repeated until the final group size reached the planned
experimental number.
The tail artery was cannulated to measure blood pres-
sure (BP). For intracranial pressure (ICP) monitoring, a
butterfly needle was percutaneously placed into cisterna
magna through foramen magnum. And then the needle
was connected to the tube of ICP monitoring device and
transferred the pressure to the transducer [25, 26]. BP
and ICP were recorded during blood injection and be-
fore the animals were killed.
Neurologic scoring
We used three behavioral activity examinations (Table 2)
to evaluate the neurologic function of rats at 24 h after
SAH as previously described [27–29]. Grading of neuro-
logic deficits was as follows: severe neurologic deficit
(scores = 4–6), moderate neurologic deficit (scores = 2–3),
mild neurologic deficit (scores = 1), and no neurologic
deficit (scores = 0).
Brain water content
Rat brains were removed at 24 h after SAH. The brains
were weighed immediately to determine the wet weight
and dried ar 80 °C for 72 h to determine the dry weight.
The percentage of brain water content was calculated
as follows: brain water content (percentage) = ((wet
weight − dry weight) / wet weight) × 100 %.
BBB permeability
We used Evans blue (EB) extravasation to assess BBB
permeability at 24 h after SAH. As described previously
Table 1 Clinical data from control and SAH cases (Continued)
45 55/F – – – – – – – –
46 49/F – – – – – – – –
47 52/M – – – – – – – –
ACA anterior cerebral artery, ACOA anterior communicating artery, ICA internal carotid artery, MCA middle cerebral artery, PCOA posterior communicating artery, BT
basilar artery, WFNS World Federation of Neurological Surgeons Grading System, GCS Glasgow Coma Score, GOS Glasgow Outcome Scale, MRS Modified
Rankin Scale
Fig. 1 Experimental SAH model of rats. Schematic diagram of the
areas used for assays. (Control) rat brain from the control group;
(SAH) rat brain from the SAH group
Table 2 Behavior scores
Category Behavior Score
Appetite Finished meal 0
Left meal unfinished 1
Scarcely ate 2
Activity Active, squeaking, or standing 0
Lying down, will stand, and walk with some
stimulation
1
Almost always lying down 2
Deficits No deficits 0
Unable to walk because of ataxia or paresis 1
Impossible to walk and stand because of ataxia and
paresis
2
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[30], EB dye (2 %, 4 ml/kg) was injected intraperitoneally
with a 3-h circulation time. Rats were anesthetized and
perfused transcardially with 0.9 % normal saline solution
(4 °C) to remove intravascular EB dye. Next, brains were
removed and weighed. Brain samples were homogenized
in physiological PBS (PH = 7.4) and centrifuged
(15,000 g, 30 min). The resulting supernatant (0.5 mL)
was added to an equal volume of 50 % trichloroacetic
acid. After incubation overnight and centrifugation
(15,000 g, 30 min, 4 °C), the supernatant was measured
at 610 nm for spectrophotometric quantification. EB
content was calculated as microgram per gram of
protein.
Perfusion—fixation and tissue preparation
Brains were harvested from rats after intracardiac perfu-
sion with 0.9 % normal saline solution (4 °C) under
anesthesia at 24 h after SAH. Brains that had obvious
clots in the prechiasmatic cistern were selected for fur-
ther analysis. After blood clots on the brain tissue were
cleared, the temporal lobe tissue was harvested on ice
and stored in −80 °C for protein extraction. For immu-
nohistochemistry (IHC) and terminal deoxynucleotidyl
transferase-mediated uridine 5’-triphosphate-biotin nick
end-labeling (TUNEL), rats were perfused with 4 % buff-
ered paraformaldehyde (4 °C) after 0.9 % normal saline
solution (4 °C) perfusion, followed by immersion in 4 %
buffered paraformaldehyde (4 °C).
Protein extraction and western blotting analysis
To extract total protein, proper size of tissue was mech-
anically homogenized in 20 mM Tris (PH 7.6, 0.2 %
SDS, 1 % Triton X-100, 1 % deoxycholate, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 0.11 IU/ml aproti-
nin) (all from Sigma, St.Louis, MO, USA). Homogenate
was centrifuged at 12,000 g for 15 min at 4 °C. The
supernatant was collected and stored at −80 °C.
Equal amounts of protein were loaded in each lane of
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and transferred to a polyvinylidene-
difluoride (PVDF) membrane. The membrane was
blocked for nonspecific binding with 5 % defatted milk
for 2 h at room temperature and incubated overnight at
4 °C with primary antibodies. For primary antibodies, we
used goat anti-PGRN (1:200; sc-11342, Santa Cruz, CA,
USA), rabbit anti-Myeloperoxidase (MPO) (1:200; sc-
16128, Santa Cruz, CA, USA), rabbit anti-zonula oc-
cludens 1 (ZO-1) (1:200; sc-10804, Santa Cruz, CA,
USA), rabbit anti-matrix metalloproteinase-9 (MMP-9)
(1:5,000; ab38898, Abcam), rabbit anti-bcl-2 (1:200; sc-
492, Santa Cruz, CA, USA), rabbit anti-cleaved caspase-
3 (1:5,000; 9661, Cell Signaling, Beverly, MA, USA), and
rabbit anti-β-actin (1:5,000; AP0060, Bioworld Technol-
ogy, Minneapolis, MN, USA). After being washed with
TBST (3 × 10 min), the membrane was incubated with
rabbit anti-goat or goat anti-rabbit horseradish peroxid-
ase (HRP)-conjugated IgG (1:5,000, BS30503 and
BS13278, Bioworld Technology, Minneapolis, MN, USA)
for 2 h at room temperature. Using the enhanced chemi-
luminescence reagent kit (Millipore Corporation, Billerica,
MA, USA), bands were visualized. Quantification was per-
formed by optical density methods using ImageJ software
(NIH), and the data was normalized to β-actin.
Enzyme-linked immunosorbent assay
Total protein was determined using a bicinchoninic acid
assay kit (Pierce Biochemicals). The inflammatory cyto-
kine levels of brain tissue were quantified using enzyme-
linked immunosorbent assay (ELISA) kits specific for
rats according to the manufacturer’s instructions (PGRN,
P28799, from Raybiotech, USA; MPO, ab119605, from
Abcam, USA; tumor necrosis factor-α (TNF-α),
950.090.096 and 865.000.096, from Diaclone Research,
France; IL-1β, 850.006.096 and 670.040.096, from Dia-
clone Research, France). The detailed method is shown
as follows: wash microwell strips twice with wash buffer.
Standard dilution on the microwell plate is as follows:
add 100 μl sample diluents, in duplicate, to all standard
wells. Pipette 100 μl prepared standard into the first
wells and create standard dilutions by transferring
100 μl from well to well. Discard 100 μl from the last
wells. Alternatively, external standard dilution in tubes is
as follows: pipette 100 μl of these standard dilutions in
the microwell strips. Add 100 μl sample diluents, in du-
plicate, to the blank wells. Add 50 μl sample diluents to
sample wells. Add 50 μl sample in duplicate, to designate
sample wells. Cover microwell strips and incubate 2 h at
room temperature. Empty and wash microwell strips five
times with wash buffer. Add 100 μl Biotin—conjugate to
all wells. Cover microwell strips and incubate 1 h at room
temperature. Empty and wash microwell strips five times
with wash buffer. Add 100 μl diluted streptavidin—HRP
to all wells. Cover microwell strips and incubate 1 h at
room temperature. Empty and wash microwell strips
five times with wash buffer. Add 100 μl of TMB sub-
strate solution to all wells. Incubate the microwell
strips for about 10 min at room temperature. Add
100 μl stop solution to all wells. Blank microwell reader
and measure color intensity at 450 nm. Inflammatory
cytokine levels in the CSF of patients were calculated as
pictogram per milliliter, and inflammatory cytokine levels
in the brain cortex of rats were calculated as pictogram
per milligram.
IHC and TUNEL
IHC was performed as previously described [31]. Rat
brains, which had been fixed with 4 % buffered parafor-
maldehyde, were embedded in paraffin and cut into 10-
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μm slices. The sections were deparaffinized and incu-
bated with 3 % H2O2 in PBS for 10 min. The sections
were blocked with 5 % normal fetal bovine serum in PBS
for 2 h followed by incubation with primary antibodies
overnight at 4 °C. For primary antibodies, we used goat
anti-PGRN antibody (1:200; sc-11342, Santa Cruz, CA,
USA) and rabbit anti-MPO antibody (1:200; sc-16128,
Santa Cruz, CA, USA). Each section was then incubated
with rabbit anti-goat or goat anti-rabbit horseradish per-
oxidase (HRP)-conjugated IgG (1:500, BS30503 and
BS13278, Bioworld Technology, Minneapolis, MN, USA)
at room temperature for 60 min. Diaminobenzidine
(DAB) and counterstaining were performed with
hematoxylin. Positive cells were identified, counted, and
analyzed under the light microscope by an investigator
blinded to the groupings. Six random high power fields
(400×) in each coronary section were selected, and the
mean percentage of positive cells in the six fields was
used for final analysis. A total of 10 sections from each
sample were used for quantification.
According to our previous study [28], TUNEL staining
was performed using an in situ cell death detection kit
(Roche, Indianapolis, IN, USA). The severity of brain
damage was evaluated by the apoptotic index, which was
defined as the average percentage of TUNEL-positive
cells. The TUNEL-positive cells were identified,
counted, and analyzed under the light microscope by
an investigator blinded to the groupings. Six random
high power fields (400×) in each coronary section
were selected, and the mean percentage of apoptotic
neurons in the six fields was used for final analysis. A
total of 10 sections from each sample were used for
quantification.
Statistical analysis
All data that were used for the statistical analysis was
presented as mean ± SEM (SPSS 17.0 and GrahPad
Prism 5.0 software). Mortality rate between groups was
analyzed by Fischer exact test. Other data was subjected
to a one-way analysis of variance followed by Tukey post
hoc test. The level of statistical significance was inferred
at p < 0.05.
Results
Levels of PGRN decreased in the CSF of SAH patients
PGRN levels as assessed by ELISA were summarized in
Fig. 2a. High levels of PGRN were detected in the control
group, while decreased levels were observed in the CSF of
SAH patients (1–3 days, p < 0.05; 4–7 days and ≥8 days,
p > 0.05). In addition, the levels of MPO, IL-1β and TNF-α
were low in the control group and increased in the SAH
groups (1–3 days, p < 0.05; 4–7 days and ≥8 days, p > 0.05)
(Fig. 2b–d). The results showed that PGRN levels
Fig. 2 ELISA analysis of PGRN, MPO, IL-β, and TNF-α in the CSF of patients. The concentration of PGRN decreased after SAH and was lowest in
the 1–3 days group (a). However, the concentration of MPO, IL-β, and TNF-α increased after SAH and was highest in the 1–3 days group (b–d).
Data are expressed as the mean ± SEM from six rats. *p < 0.05 compared with the control group, nsp > 0.05 compared with the control group
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decreased after SAH, which may be associated with the
levels of MPO, IL-1β, and TNF-α.
General observations and mortality rate
After SAH, no statistical difference in physiological pa-
rameters (BP and ICP) was observed among the groups
(data not shown). There were 221 rats used in the
present study and the mortality rates during and after
surgery were as follows: (1) the sham group (0 of 6 rats),
the SAH groups on 12 h (1 of 7 rats), 1 days (2 of 8
rats), 3 days (1 of 7 rats), 5 days (2 of 8 rats), and 7 days
(2 of 8 rats); (2) the sham group (0 of 30 rats), the SAH
group (6 of 36 rats), the SAH + PBS group (5 of 35 rats),
the SAH + PGRN (1 ng per rat) (2 of 14 rats), the SAH +
PGRN (3 ng per rat) (3 of 13 rats), the SAH + PGRN
(10 ng per rat) (5 of 35 rats), and the SAH + PGRN (15 ng
per rat) (2 of 14 rats).
Temporal alterations of PGRN protein levels after
experimental SAH in rats
The time course of PGRN protein levels were assessed
by western blotting. PGRN protein levels decreased at
12 h after SAH with the lowest level observed at 24 h
(Fig. 3a). According to the western blotting results, we
selected the sham group and the 24-h group (lowest
level of PGRN) for IHC. PGRN-positive cells markedly
decreased at 24 h after SAH compared with the sham
group (Fig. 3b).
Fig. 4 Effects of PGRN on neurologic scores (a) and brain water content (b) at 24 h after SAH. Neurological function of rats was impaired and
brain water content increased significantly at 24 h after SAH compared with rats in the sham group. R-PGRN (3, 10, and 15 ng/rat) dramatically
increased neurological scores and alleviated brain edema at 24 h after SAH, but r-PGRN at a dose of 1 ng/rat did not significantly affect
neurological scores and brain edema. No difference was detected between the untreated SAH group and the PBS treated SAH group.
Data are expressed as the mean ± SEM from six rats. ***p < 0.001 and **p < 0.01 compared with the sham group, nsp > 0.05 compared with
the SAH group, ###p < 0.01, ##p < 0.01, and #p < 0.05 compared with the SAH group
Fig. 3 Western blot analysis and IHC of PGRN in the brain cortex of rats. PGRN protein levels decreased after SAH and were lowest at 24 h after
SAH (a). IHC revealed that there were more PGRN-positive cells in the sham group compared with the 24-h SAH group (b). Data are expressed as
the mean ± SEM from six rats. *p < 0.05 compared with the control group
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R-PGRN significantly improves neurologic function and
reduces brain water content at 24 h after SAH
To test the neuroprotective effects of r-PGRN on EBI,
we evaluated the neurologic function and brain water
content at 24 h after SAH. In this study, r-PGRN was
given at four different concentrations to SAH rats. As
shown in Fig. 4, treatment with r-PGRN at 3, 10, and
15 ng/rat dramatically ameliorated neurologic function
(p < 0.01, p < 0.001) and brain edema (p < 0.05, p < 0.01).
However, r-PGRN at 1 ng/rat had no significant effect.
In addition, r-PGRN at a higher dose of 15 ng/rat did
not exhibit a better neuroprotective effect than that at
10 ng/rat. These results suggested that r-PGRN could al-
leviate EBI and that r-PGRN at 10 ng/rat exhibited the
most beneficial effect. Therefore, we selected 10 ng/rat
for further experiments.
PGRN suppresses the recruitment of neutrophils at 24 h
after experimental SAH in rats
Western blotting (Fig. 5a) showed that the protein levels
of MPO significantly increased in the SAH and SAH +
PBS groups (p < 0.01) and decreased in the SAH +
PGRN group (p < 0.05). IHC (Fig. 5b) revealed that
MPO-positive cells in the SAH and SAH + PBS groups
were significantly increased relative to that of the sham
group (p < 0.001). Following r-PGRN treatment, the
numbers of MPO-positive cells decreased (p < 0.01).
R-PGRN reduces the production of pro-inflammatory
cytokines at 24 h after experimental SAH in rats
ELISA was used to measure the production of pro-
inflammatory cytokines (TNF-α and IL-1β). As shown in
Fig. 6, the concentrations of cytokines were significantly
increased at 24 h after SAH (p < 0.001) and significantly
reduced after treatment with r-PGRN (p < 0.01).
Brain edema is ameliorated with r-PGRN treatment at
24 h after experimental SAH in rats
To demonstrate the effects of PGRN on brain edema,
BBB permeability and protein levels of MMP-9 and ZO-
1 were tested at 24 h after SAH. MMP-9 levels and ZO-
1 degradation significantly increased in the SAH and
SAH + PBS groups (p < 0.01; Fig. 7a, b) and were largely
reduced after r-PGRN treatment (p < 0.05; Fig. 7a, b). As
Fig. 5 Western blot analysis and IHC of MPO in the brain cortex of
rats 24 h after SAH. MPO protein levels increased after SAH and
significantly decreased following r-PGRN treatment (a). IHC revealed
that MPO-positive cells decreased after treatment with PGRN, which
significantly increased after SAH (b). There was no difference
between the untreated SAH group and the PBS-treated SAH
group. Data are expressed as the mean ± SEM from six rats. ***p <
0.001 and **p < 0.01 compared with the sham group, nsp > 0.05
compared with the SAH group, ##p < 0.01 and #p < 0.05 compared with
the SAH group
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shown in Fig. 7c, EB indicated that BBB permeability in-
creased after SAH (p < 0.001) and dramatically reduced
after PGRN treatment (p < 0.01).
Increased PGRN decreases neural cell apoptosis at 24 h
after experimental SAH in rats
To illustrate the effects of PGRN on neural cell apop-
tosis, the levels of apoptosis-related proteins (bcl-2 and
cleaved caspase-3) and extent of TUNEL were moni-
tored at 24 h after SAH in our study. As shown in
Fig. 8a, b, Bcl-2 levels decreased after SAH (p < 0.01)
and were upregulated by r-PGRN treatment (p < 0.05).
In contrast, cleaved caspase-3 levels increased after SAH
(p < 0.01) and reduced after treatment with r-PGRN
(p < 0.05). In addition, TUNEL (Fig. 8c) revealed that
there were few TUNEL-positive cells in the sham
group, whereas the apoptotic index in the SAH group
was significantly higher than that of rats in the sham
group (p < 0.001). The percentage of TUNEL-positive
cells reduced after r-PGRN treatment (p < 0.01).
Discussion
In the present study, we demonstrated for the first time
that PGRN decreased in the CSF of SAH patients and
reached a maximum low at 1–3 days after SAH. In
addition, the decrease of PGRN was associated with an
increase in MPO, IL-1β, and TNF-α. To clarify the role
of PGRN following SAH, we continued our research in
experimental rats. PGRN decreased in the brain of rats
after SAH with a maximum low at day 1. Furthermore,
we found that PGRN treatment alleviated EBI by sup-
pressing neutrophil recruitment. Our results suggested
that increased PGRN was involved in inhibiting the
neutrophil-mediated inflammatory response after SAH.
EBI has been demonstrated as a primary cause of high
morbidity and mortality [1]. Therefore, there is a need
to devise therapeutic strategies for improving outcomes
of SAH patients [5]. A large body of evidence demon-
strates that inflammation appears to be the proegumenal
cause of brain injury after SAH [32] and that patients
with high levels of cytokines (such as IL-1β and TNF-α)
would have unfavorable outcomes and symptoms for
clinical deterioration [33]. Inflammation induces apop-
tosis [34] and leads to BBB disruption by increasing
endothelial permeability and vessel diameter [35]. In
addition, a number of studies have indicated the critical
role of neutrophils in the inflammatory response [36].
Neutrophils are among the first cells in the blood to re-
spond after brain injury and are a main cause of brain
injury [11, 37]. Neutrophils release pro-inflammatory
mediators and chemotactic agents, enhancing the
recruitment of further neutrophils and exacerbating
inflammation [38]. Activated neutrophils can modulate
the level of MMP-9 [39], which is reported to participate
in BBB damage and brain edema by degrading tight
junction proteins and basal lamina proteins after SAH
[40, 41]. Previous research has shown that limiting
neutrophil activity reduces vascular collagenase activity
and microvessel wall injury and increases in vessel
permeability, all of which alleviates brain injury after
SAH [42].
Previous studies have demonstrated the anti-
inflammatory role of PGRN in CNS diseases, such as
neurodegenerative diseases and ischemic stroke [19, 43],
and that deficiency of PGRN resulted in exaggerated
inflammation and BBB disruption [13]. Moreover, PGRN
modulates neutrophilic inflammation by inhibiting the
activation and recruitment. However, activated neutro-
phils can secrete neutrophil elastase (NE) to degrade
PGRN into individual granulin peptides, which act in
the opposite manner, stimulating the production of pro-
inflammatory cytokines [17, 34]. Therefore, we hypothe-
sized that a decrease in PGRN levels potentiates the
inflammation induced by EBI and that high levels of
Fig. 6 ELISA analysis of IL-β and TNF-α in the brain cortex of rats 24 h after SAH. The concentrations of IL-β (a) and TNF-α (b) significantly
increased at 24 h after SAH and decreased after administration of r-PGRN. No difference was detected between the untreated SAH group and the
PBS-treated SAH group. Data are expressed as the mean ± SEM from six rats. ***p < 0.001 compared with the sham group, nsp > 0.05 compared
with the SAH group, ##p < 0.01 compared with the SAH group
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PGRN may inhibit inflammation by suppressing neutro-
phil activation. In our study, we found that PGRN levels
decreased in the CSF of SAH patients. In addition,
changes in PGRN levels occurred in a time-dependent
manner, in contrast to MPO, IL-1β, and TNF-α levels.
Based on these results, we suggest that PGRN can allevi-
ate EBI and that this protective role is related to inflam-
mation. This hypothesis is supported in our animal
study. We demonstrated that PGRN decreased after
SAH in the brain of rats and that increased PGRN could
alleviate EBI. We found r-PGRN treatment could sup-
press neutrophil recruitment and reduce the production
of pro-inflammatory cytokines such as TNF-α and IL-1β.
In addition, we demonstrated that r-PGRN alleviated
EBI after SAH. Our results were also in line with Friedrich
et al.’s findings [38] and confirmed that neutrophils
contributed to earlier inflammation after SAH. Further-
more, present results show that reduction in PGRN is one
of the important contributors of neutrophil-induced
inflammation.
Brain edema is a key factor related to the mortality
and poor outcome after SAH [44]. Moreover, it is associ-
ated with BBB breakdown caused by disassembly of tight
junctions and endothelial cell contraction [45]. A previ-
ous study indicates that PGRN deficiency leads to major
alterations in BBB structure and function [13]. In our
study, we found that r-PGRN administration reduced
the levels of MMP-9 and concomitantly restored the
levels of ZO-1, which is one of the tight junction
proteins. Meanwhile, BBB permeability, as assessed by
extravasation of EB dye in the brain, was largely re-
duced by r-PGRN. These findings demonstrated that
PGRN protected the BBB by blocking the increase of
MMP-9 and the degradation of tight junction proteins
after SAH.
Previous studies have shown that apoptosis is another
contributor to a poor outcome after SAH [46] and can
be reduced by PGRN [47]. Our current study observed
that PGRN decreased the levels of apoptosis-related pro-
teins (Bcl-2 and cleaved caspase-3). Moreover, TUNEL
Fig. 7 The effect of PGRN on MMP-9 and ZO-1 levels in the brain
cortex of rats and extravasation of EB dye at 24 h after SAH. Western
blotting revealed that MMP-9 levels in the SAH group were
significantly higher than that in the sham group. R-PGRN treatment
reduced the levels of MMP-9 (a). ZO-1 protein levels in the SAH group
were significantly lower than that in the sham group. Treatment with
r-PGRN markedly increased ZO-1 levels (b). EB showed significantly
higher BBB permeability in the SAH group compared with the sham
group. R-PGRN administration significantly reduced BBB permeability
induced by SAH (c). There was no difference between the untreated
SAH group and the PBS-treated SAH group. Data are expressed as the
mean ± SEM from six rats. ***p < 0.001 and **p < 0.01 compared with
the sham group, nsp > 0.05 compared with the SAH group, ##p < 0.01
and #p < 0.05 compared with the SAH group
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demonstrated that PGRN could reduce neuronal apop-
tosis after SAH.
Accumulating evidence has demonstrated the protect-
ive role of PGRN in brain injury, and a recent study
showed that PGRN could reduce neuronal cell death
after SAH [48]. However, the anti-inflammatory role of
PGRN after SAH is still unknown. Our study indicated
an anti-inflammatory role of PGRN on EBI after SAH by
inhibiting the recruitment and activation of neutrophils,
which is emerging as a hallmark of vascular inflamma-
tion [9] and is closely related to BBB breakdown [49].
Based on previous studies and our study, the protective
role of PGRN on EBI has been identified [48]. However,
further studies are needed to validate the exact role and
mechanism of PGRN after SAH.
Although our study has some limitations, such as the
lack of different severities of SAH and the short-term
follow-up in patients, we demonstrated that PGRN could
reduce neuronal death, alleviate brain edema, preserve the
BBB, and inhibit inflammation by suppressing neutrophil
recruitment. However, these effects may act via different
pathways, such as the sortilin and nuclear factor-κB signal
pathway. Hence, further studies are needed to explain the
full role of PGRN in the pathophysiology of SAH.
Fig. 8 Effect of PGRN on neural cell apoptosis 24 h after SAH. Western blotting revealed Bcl-2 levels in the SAH group were significantly reduced
compared with sham. R-PGRN treatment increased the levels of Bcl-2 (a). Cleaved caspase-3 levels in the SAH group were significantly higher than
the sham group. Treatment with r-PGRN markedly reduced cleaved caspase-3 levels (b). The number of TUNEL-positive cells increased after SAH
and reduced after r-PGRN treatment (c). No difference was detected between the untreated SAH group and the PBS-treated SAH group. Data are
expressed as the mean ± SEM from six rats. ***p < 0.001 and **p < 0.01 compared with the sham group, nsp > 0.05 compared with the SAH group,
##p < 0.01 and #p < 0.05 compared with the SAH group
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Conclusions
In conclusion, our study demonstrated that the levels of
PGRN decreased in the CSF from SAH patients and in
the brain cortex of rats after SAH. In addition, an
administration of r-PGRN alleviated EBI, which was
associated with inhibiting the inflammatory reaction
by suppressing neutrophil recruitment. Moreover,
PGRN inhibited BBB disruption and reduced neural
cell apoptosis, which are both important contributors
to a poor outcome after SAH.
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